Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Morgan Stanley initiates Power One at underwieght and 3.75$ price target.
not a very positive initiation, first analyst with underweight.... but why?
Dupe, new WAG 1214
sorry!
did we just hit 5.93$ today? lol
thank you for the earnings update.
up 5.30$ the pinch is wrapping up!! lol
we were here at the right time i just missed my call on it.
still moving forward. bought a other stock i am up on it.
pwer calls are up 112%. :)
gl sir.
i added the november 5 calls on watch. they are up 50% since my add. i might switch to 4.00$ or a longer timeframe, depending on what the stock will do in the coming weeks into earnings and further. looks like the pinch is wrapping up? the green line never got to -20 but the white one was near 40 based on the chart you posted, i sticked it.
the weekly MACD could do anything, lets see what happens monday/tuesday.
have a good weekend.
stocktrader.
what a bouce, this is why i like this stock. what does the pinch chart says? :)
have a good rest of the day.
stocktrader
keep an eye on JAZZ.
always good for a play. 50.00$ should be reachable in the next 2 months imo. recently they aquired a company wich brings them another 100million in revenue this year. Jazz is based in Palo Alto where Apple and Facebook are at home.
Jazz Pharmaceuticals And Azur Pharma Agree To Combine To Form Jazz Pharmaceuticals Plc
– Combined company would have a diversified product portfolio, strong cash flow and expected annual revenues of more than $475 million –
– Jazz Pharmaceuticals stockholders to own slightly under 80 percent of combined entity; Azur Pharma stockholders to own slightly more than 20 percent –
– Conference call today at 4:30 PM ET to discuss transaction –
PALO ALTO, Calif. and DUBLIN, Sept. 19, 2011 /PRNewswire/ — Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) and Azur Pharma Limited today announced that the companies have agreed to combine in an all-stock transaction that creates a specialty pharmaceutical company incorporated in Ireland with a diversified portfolio of products currently marketed in the United States (US). The combined company would be named Jazz Pharmaceuticals plc.
Azur Pharma is a privately-held, profitable specialty pharmaceutical company headquartered in Dublin, Ireland with US operations in Philadelphia. The company markets ten specialty pharmaceutical products in the US in the central nervous system (CNS) and women’s health areas, with expected 2011 net sales of approximately $95 to $100 million.
PWER Key Stats + Insider transactions:
http://finance.yahoo.com/q/ks?s=PWER+Key+Statistics
http://finance.yahoo.com/q/it?s=PWER+Insider+Transactions
Lowest EV/EBITDA Ratio in the Electronic Components Industry Detected for Power-One (PWER, VSH, AVX)
Below are the three companies in the Electronic Components industry with the lowest enterprise value to EBITDA (EV/EBITDA) ratios. EV/EBITDA is an important metric used in valuing comparable companies. It is capital structure neutral and generally the lower the ratio, the more undervalued the company is believed to be.
Power-One (NASDAQ:PWER) is lowest with an EV/EBITDA ratio of 1.18. Power-One, Inc. designs and manufactures power conversion products primarily for the communications infrastructure market. The Company sells its products to customers in the communications, automatic test equipment, medical equipment, industrial, transportation, and other electronic equipment industries. Yesterday, Power-One traded 3.2 million shares vs. average volume of 2.5 million shares per day. The stock outperformed the Dow (3.6% to the Dow's 1.3%) and outperformed the S&P 500 (3.6% to the S&P's 0.8%) during yesterday's trading.
http://www.fnno.com/story/fast-lane/331-lowest-evebitda-ratio-electronic-components-industry-detected-power-one-pwer-vsh-avx-fast-lane
ok. today is last trading day in september. depending on how we close today, the new monthly/weekly cnadlestick will start under/above or at the moving avreges. overall i think we will break down theese in the longterm.
its not easy to predict where the bounce will come, easpecially with a stock like this. i am also not an expert.
what we know is, PWER has been a good earnings play in the past. next earnings release will be Oct. 28.
with that pinch setup and decreasing short position, i think its worth a follow in the month of october.
http://biz.yahoo.com/research/earncal/p/pwer.html
current low is 4.54$ and we are trading right at it. the monthly switch this weekend is risky imo with the weekly/monthly MACD going into the red.
this is what i see and i would not feel save to buy in over the weekend. :) i am going to wait even if i should miss a bounce. we might see this pinch set up getting tighter next week or so...lets see aswell what eod brings. yesterday there was nice buying...
gl and thank for the charts.
stocky :)
ohh ok. yeah i folllow pinchers. actually love pinch plays.
aswell if you look on the weekly and monthly chart were sitting on big lines.
how long does it takes for the pinch to wrap up in your opinion?
Short of float went from 46% to 36.2% as of today.
lets see if we get a bounce arround 4.80$.
tuff days...
greetz
stocktrader
:)
this thing just hit a buck!
hehe :D tooooo tha moooooon! 0.26x0.27$, 0.29 in play.
there is one at 0.86$? nice!
0.25x0.26$ lgfty moves on air!
woohaa so LGFTY had a buyer eod. it has been on my watch since the reopen. thanks for the chart.
just found this board. looks pretty well imo. good work.
stocktrader
awsome day here, again. 50.00$ is in play imo.
PWER bleeding and printing new 52 week lows. SMA outlook fades for solars.
cant wait for this thing to bottom out.
SMA Solar Slumps to 2-Year Low in Frankfurt After Reducing Outlook
By Stefan Nicola - Sep 19, 2011 6:11 PM GMT+0200
SMA Solar Technology AG (S92), Germany’s biggest solar-power company by market value, dropped to a two- year low in Frankfurt trading after reducing its profit forecast amid weaker-than-expected demand for rooftop systems.
SMA plunged 12 percent to 49.25 euros at 5:30 p.m. local time, the lowest closing price since Sept. 2, 2009. The company expects earnings before interest and tax of 220 million euros ($300 million) to 300 million euros in fiscal 2011, down from an earlier estimate of 315 million euros to 475 million euros.
“The demand for solar power plants has only marginally improved in many solar markets after the summer months,” Niestetal-based SMA said in a statement. “Contrary to managing- board expectations, SMA has established only a minor upturn in the high-volume business of solar inverters for roof systems.”
SMA is the biggest maker of inverters, devices that convert electricity generated in solar panels for the grid. It’s among solar companies including Bonn-based Solarworld AG to experience slumping sales in Europe, where Germany, Italy and France have cut premiums paid for power from panels over the past 12 months.
Power-One Inc. (PWER), a Camarillo, California-based peer of SMA, fell as much as 6.9 percent in New York, and traded down 4.4 percent at $6.48 as of 11:30 a.m. local time. Suntech Power Holdings Co. and LDK Solar Co., the world’s biggest solar-panel producers, each dropped as much as 10 percent.
Drag on Market
“SMA’s outlook has always been a very reliable indicator for the overall market and that’s why you see most solar companies falling today,” said Lars Dannenberg, an analyst at Berenberg Bank in London. The solar market slump may cut Germany’s installations to about 5 gigawatts this year, he said.
Bloomberg New Energy Finance, a London-based researcher, estimated in March that Germany would install at least 6 gigawatts of panels in 2011, followed by Italy with at least 4.5 gigawatts.
SMA shares have tumbled 29 percent this year, outperforming a 45 percent decline in the Global Leaders Solar Inverter Index.
On Aug. 12, SMA jumped 18 percent after posting first-half earnings that beat analyst estimates and forecasting higher demand in the second half. Today, it reported a “pleasing development” in the market for large-scale solar power plants, adding that it can’t compensate for the “weak commercial order situation.”
The company also revised its sales outlook, reducing its target to as much as 1.7 billion euros for fiscal 2011 from an earlier estimate of as much as 1.9 billion euros.
http://www.bloomberg.com/news/2011-09-19/sma-solar-shares-slump-to-two-year-low-after-lowering-outlook.html?cmpid=yhoo
from 0.05$ to 0.06$ nice! lets se what it does @ the 50dma.
3 Stocks Shaking the Market
By Rich Duprey | More Articles
September 14, 2011 | Comments (1)
Some stocks are one-hit wonders, making a big splash when they first appear, then quickly fizzling into obscurity or oblivion. But for other stocks, that initial big move is only a preview for even bigger and better gains to come.
Today, we've listed three stocks that made some of the biggest upward moves over the past month, despite the incredible volatility in the market, which we'll pair with the ratings issued by our Motley Fool CAPS community. The higher each stock's rating, the greater CAPS members' faith in that company's ability to keep on beating the market.
Stock
1-Month Change
CAPS Rating
(out of 5)
Optimer Pharmaceuticals (Nasdaq: OPTR ) 66.5% **
Eastman Kodak (NYSE: EK ) 53.3% *
Majesco Entertainment (Nasdaq: COOL ) 43.7% **
Source: FinViz.com.
While you were out, the markets collapsed and may continue to do so as concerns over Europe escalate. So before we get shaken out again, let's see why the CAPS community thinks these three companies might continue to outperform the market.
A mighty temblor
Ignore the wider losses that Optimer Pharmaceuticals reported this past quarter, since it was ramping up the launch of its diarrhea drug Dificid. The launch is going well, with sales, while small at $3.9 million, doubling analyst estimates. Approved by the FDA back in May, Dificid -- which is used to treat hospital-acquired diarrhea -- was launched in July.
The drug -- which was found to be non-inferior to ViroPharma's Vancocin in achieving its goals at the end of treatment, but superior to it by having a sustained clinical response -- will be co-promoted with Cubist Pharmaceuticals (Nasdaq: CBST ) over a two-year period. A second agreement with Astellas will have that pharmaceutical market the drug pretty much everywhere outside of the U.S. Looking to target more than 2,000 hospitals domestically, and with costs associated with the ailment estimated to be around $3.2 billion annually, there's a fairly large market to tackle.
Insiders have been buying up shares, but the CAPS community has been rather sanguine about Optimer's potential, with just 78% expecting it to outperform the market. Add your thoughts on where the drug developer will go on the Optimer Pharmaceuticals CAPS page and put it on your watchlist to keep track of its progress.
Picture this
Euphoria over the rich valuation suddenly assigned to patent portfolios sent Eastman Kodak's shares soaring. A $4.5 billion payout for a bankrupt company's IP and a $12.5 billion buyout of Motorola Mobility (NYSE: MMI ) by Google had investors sending shares of everyone from InterDigital (Nasdaq: IDCC ) to VirnetX (AMEX: VHC ) higher thinking they, too, would be able to cash in.
Kodak has thought its rather deep portfolio might be worth a pretty penny or two. It floated the idea that it was considering going to market to see what the patents might fetch, particularly the one with which they've been trying to bludgeon Apple and Research In Motion.
Although some analysts pegged Kodak's patent value at about $3 billion, that might be wishful thinking. Kodak's patents may not be worth anywhere near what the market was willing to pay for mobile communications patents, as a rising tide doesn't necessarily lift boats in a different port. Kodak's star has fallen considerably from its heyday, and even if it's able to wrangle a few dollars from its IP, the fast-fading brand likely won't attract the kind of money an up-and-coming one would.
Just 58% of the CAPS All-Stars rating Kodak think it can beat the market. Tell us in the comments section below or on the Eastman Kodak CAPS page if you see it developing any growth from here.
Cool, dude
When Microsoft surprised the market by selling boatloads of its Kinect motion-sensing systems (10 million as of March), it gave a much-needed boost to the software industry that was weakened by the recession. Yet, it has only two real breakout hit games to speak of so far, Dance Central and Kinect Sports. Both are multimillion-unit sellers, but you'd be hard-pressed to name another big one.
Similarly, game maker Majesco Entertainment has relied upon the mammoth success it enjoyed with its Zumba Fitness title, which accounts for three-quarters of all its revenues. Although it acquired free-to-play sports title developer Quick Hit to bolster its social-gaming division, it's doubling down on Zumba by coming out with a follow up release of the title. To keep growing, though, it's going to need a more robust lineup.
While the CAPS community is bullish on Majesco and CAPS member Jonock sees it doubling in value over the next three months, should such faith be placed in a company whose fortunes are tied to one title? Let us know on the Majesco Entertainment CAPS page if you think the game is rigged against it succeeding.
Shake, rattle, and roll
With these stocks shaking the market this past month it pays to start your own research on them at Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made, all from a stock's CAPS page.
http://www.fool.com/investing/general/2011/09/14/3-stocks-shaking-the-market.aspx
Sept. 14, 2011 North Springs Resources Acquires Gold Property in Prestigious Mineral Ridge Mining District, Nevada, USA
LAS VEGAS, NEVADA, Sep 14, 2011 (MARKETWIRE via COMTEX) -- North Springs Resources Corp. NSRS +600.00% ("The Company", "North Springs") is pleased to announce that it has recently acquired the mineral rights to the North Springs Gold Property, which is located in the prestigious Mineral Ridge Mining District, Esmeralda County, Nevada USA. The decision to acquire this property was a strategic decision by the Management of North Springs Resources to create a corporate identity and direction.
"The North Springs Gold Property is located in one of the premiere mining regions in Nevada and we are committed to exploring the potential of this property," stated Harry Lappa, President of North Springs Resources. "The North Springs Gold Project currently has well defined drill targets based on geologic mapping and surface sampling; presently demonstrating excellent potential to discover a world-class gold deposit. Management intends on aggressively growing the company, and with the recent increase in gold prices, we want to build a strong gold exploration company around properties with a strong possibility for a significant gold discovery. We believe that this acquisition is just the beginning for North Springs Resources."
The North Springs Gold Project is located about 10 miles northwest of Silver Peak, Nevada on the west side of Mineral Ridge. The land package consists of approximately 36 unpatented federal lode mining claims that cover two separate areas, the Roadrunner Block and the Coyote Summit Block. The geology at North Springs is similar to that of the nearby Mineral Ridge Mine, and indeed, may actually be a continuation of the same gently-dipping, sheet-like body which hosts gold mineralization at the Mineral Ridge Mine.
Both the North Springs Gold Property and the Mineral Ridge deposits are situated along a regional northwest trending, large anticline known as the Mineral Ridge Metamorphic Core Complex. This complex contains extensive high-grade gold veins (52 miles of underground workings on low-angle veins) and stacked, low angle, shear zones which has been open pit mined in several deposits. The Mineral Ridge deposits contain a current resource of 500,000 ounces gold. The North Springs Gold Property occupies very similar geology, alteration and mineralization, geochemistry and structural setting to the Mineral Ridge deposits, though there is no resource estimate known at this time. Sampling to date has identified gold mineralization up to 0.8 ounces per ton from surface workings. The North Springs Gold Project contains several untested gold targets that include open-pit, disseminated mineralization and high-grade shear zones and feeder veins, such as those that have been mined by several mining companies at the nearby Mineral Ridge deposits.
For additional information, please visit www.northspringsresources.com .
http://www.marketwatch.com/story/north-springs-resources-acquires-gold-property-in-prestigious-mineral-ridge-mining-district-nevada-usa-2011-09-14-93550?reflink=MW_news_stmp
i doubt that by looking at the volume. is there 3-4 in a row on the bid? than they short the bid...
this is not trading right. it should bee over 0.80$ but instead its sinking. smh...
EVGI dead, some ask slapping is due here. where is all the volume gone from bod.
On September 7, 2011, North Springs Resources Corp., a Nevada corporation (the "Company") issued a ten percent (10%) Promissory Note (the “Note”) to Kazuo Holdings, Inc. (“Kazuo”) in the amount of five thousand US dollars ($5,000), to evidence funds previously lent by Kazuo to the Company on June 22, 2011. The Note earns simple interest accruing at ten percent (10%) per annum and is due upon ten (10) days written notice by Kazuo.
The description of the Note is a brief summary only and is qualified in its entirety by the respective terms set forth therein. A copy of the Note evidencing the June 22, 2011 loan is filed as Exhibit 10.1 to this Current Report on Form 8-K.
another chinese fall. thats the third one in a row.
WATG LGFTY PUDA.
awsome drop on no volume.
how did you know they would drop it exactly to 0.036$. my prediction was 0.04$
thank you!! added membermark.
today is the first day of a new beginning, we about to make history!
Hay
Can i change my name from stockfreak001 to stocktrader001 or stockhunter001 etc..? :)
that would be awsome!!!
TIA!
from the 10-Q:
Management stock options
During the year ended December 31, 2010, the Company granted 28,500,000 stock options with a grant date value of $1,581,327 to five directors and one officer at an exercise price of $0.0714 per share. The stock options expire on December 31, 2020. Holders of the management stock options may exercise the options by paying the exercise price to the Company or on a cashless basis upon the approval of the Company’s board of directors. Should the options be exercised on a cashless basis, the Company will issue common shares of the Company with a market value equal to the intrinsic value of the options at the close of trading on the date of exercise. The management stock options were not issued under the Company’s Non-Qualified Stock Option Plan and as at July 1, 2010, the Company filed a registration statement under the Securities Act of 1933 to register the underlying shares. Accordingly, any shares issuable upon the exercise of these options will be free trading securities.
The fair value for stock options granted was estimated at the date of grant and revalued on June 30, 2011 using the Black-Scholes option-pricing model and the weighted average fair value of stock options granted during the six months ended June 30, 2011 and 2010 was $0.06 and $0.07 per share, respectively.
if this happens, look for 0.04$-0.044$ to hold.
you can not compare thoose two stocks together.